Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Mylan to Buy Abbott’s Generic Drug Business Outside U.S. for $5.3 Billion

14/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzmvmtyvnti3l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

Abbott Laboratories said on Monday that it had agreed to sell its established generic drug business outside the United States to the generic drug maker Mylan in an all-stock deal that valued at about $5.3 billion.

Under the deal, Abbott will take a 21 percent stake worth about $5.3 billion in a new company that combines Mylan’s existing business with Abbott’s developed markets pharmaceuticals operations in Europe, Japan, Canada, Australia and New Zealand.

The transaction will allow Mylan to engage in a so-called inversion: the Pennsylvania company would reincorporate in the Netherlands to lower its corporate taxes and to free up cash held in overseas entities.

Mylan, whose headquarters are in Pittsburgh, unsuccessfully pursued the Swedish drug maker Meda this year in hopes of engaging in an inversion.

“We have been actively looking at a wide range of opportunities, and the acquisition of this business is absolutely the right next strategic transaction for Mylan as it builds on our strong momentum, expands and further diversifies our business in our largest markets outside of the U.S.,” Robert J. Coury, the Mylan executive chairman, said in a statement.

This article has been extracted from http://dealbook.nytimes.com, please click on this link to read the article in full http://dealbook.nytimes.com/2014/07/14/mylan-to-buy-generics-drugs-business-outside-u-s-from-abbott-for-5-3-billion/

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdgvmtqvmtmvmjcvmjgvnja2l2nsb3rozxmuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

In Her Shoes... From Market Stall to Recruitment

2017-08-14 14:00:00 +0100

From the melee of the market stall to placing candidates in high-flying IT roles, life's always on the up from market-trader-turned-recruiter, Lois Hinken (22). She took the time to talk to us about how her experience in the cut throat world of the market has helped her in the world of global talent acquisition. As a 360 recruitment consultant for Montash, her negotiation skills and "go get it" attitude have helped her thrive. "I started working on the ...

W1siziisijiwmtcvmdgvmdcvmtmvmtcvntqvnze3l1vudgl0bgvkigrlc2lnbiaomikuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

Will AI Cost Us Our Humanity?

2017-08-07 15:00:00 +0100

As technology evolves, artificial intelligence is becoming increasingly mainstream, and it will inevitably start to impact the way we interact. On the one hand, AI has the potential to solve a variety of problems and streamline our lives and our work. But will this come at the cost of the all-important human touch? A foreshadowing statistic claims that by 2020, 85% of client interactions will be managed without a human[1]. But can there really be an alg...